LivaNova (NASDAQ:LIVN) Price Target Raised to $73.00

LivaNova (NASDAQ:LIVN) had its price target upped by Barclays from $67.00 to $73.00 in a research report released on Friday,Benzinga reports. Barclays currently has an equal weight rating on the stock.

A number of other equities analysts have also commented on LIVN. KeyCorp began coverage on shares of LivaNova in a report on Friday, December 19th. They issued an “overweight” rating and a $81.00 price target on the stock. Robert W. Baird set a $75.00 target price on LivaNova in a research note on Tuesday, December 16th. Stifel Nicolaus set a $80.00 price target on LivaNova in a research note on Wednesday. Needham & Company LLC upped their price objective on LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of LivaNova in a report on Monday, December 29th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $74.78.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $70.60 on Friday. The stock’s 50-day simple moving average is $64.74 and its two-hundred day simple moving average is $59.14. LivaNova has a twelve month low of $32.48 and a twelve month high of $71.92. The firm has a market capitalization of $3.86 billion, a P/E ratio of -15.83 and a beta of 0.92. The company has a quick ratio of 1.16, a current ratio of 1.36 and a debt-to-equity ratio of 0.29.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.80 by $0.06. The company had revenue of $360.86 million during the quarter, compared to analyst estimates of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.LivaNova’s revenue was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.81 earnings per share. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. As a group, equities analysts anticipate that LivaNova will post 2.85 EPS for the current fiscal year.

Institutional Investors Weigh In On LivaNova

Institutional investors have recently bought and sold shares of the stock. Hantz Financial Services Inc. raised its stake in LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after acquiring an additional 267 shares during the period. State of Wyoming bought a new stake in shares of LivaNova during the 2nd quarter valued at $31,000. EverSource Wealth Advisors LLC lifted its stake in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares in the last quarter. Quarry LP purchased a new position in shares of LivaNova during the 3rd quarter valued at $36,000. Finally, UMB Bank n.a. boosted its holdings in LivaNova by 63.0% in the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after buying an additional 306 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.